Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2019 Dec 11

PMID 31819577

Citations 7

Authors

Sam Pearson

Noppadol Kietsiriroje

Ramzi A Ajjan

Affiliations

Soon will be listed here.

Abstract

In recent years, newer drug classes for the treatment of type 2 diabetes mellitus have been released with significant effects on glucose lowering and weight reduction. One of the most promising classes in achieving these goals has been the glucagon-like peptide (GLP)-1 agonists. However, a difficulty with the use of these agents is the need for subcutaneous injections, which can be inconvenient to individuals living with type 2 diabetes. More recently, a GLP-1 agonist has been developed, semaglutide, that can be administered orally which has at least similar effects to the subcutaneous preparation from which this compound is derived. In this review article, we discuss the glycemic and cardiovascular effects of the GLP-1 agonists with special emphasis on oral semaglutide and the potential role of this therapy in individuals with type 2 diabetes.

Citing Articles

Therapeutic proteins: developments, progress, challenges, and future perspectives.

Kumar V, Barwal A, Sharma N, Mir D, Kumar P, Kumar V 3 Biotech. 2024; 14(4):112.

PMID: 38510462 PMC: 10948735. DOI: 10.1007/s13205-024-03958-z.

RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus.

OBrien J, Chouliaras L, Sultana J, Taylor J, Ballard C Alzheimers Res Ther. 2022; 14(1):169.

PMID: 36369100 PMC: 9650797. DOI: 10.1186/s13195-022-01103-7.

Drugs for Treating Obesity.

Ryan D Handb Exp Pharmacol. 2021; 274:387-414.

PMID: 34783910 DOI: 10.1007/164_2021_560.

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?.

Ryan D J Obes Metab Syndr. 2021; 30(3):196-208.

PMID: 34518444 PMC: 8526285. DOI: 10.7570/jomes21033.

Type 2 Diabetes in Youth.

Rao G, Jensen E Glob Pediatr Health. 2021; 7:2333794X20981343.

PMID: 34036121 PMC: 8126957. DOI: 10.1177/2333794X20981343.

References

Karsdal M, Byrjalsen I, Henriksen K, Riis B, Christiansen C . Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy. Eur J Clin Pharmacol. 2009; 66(1):29-37. DOI: 10.1007/s00228-009-0735-3. View

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

Baekdal T, Thomsen M, Kupcova V, Hansen C, Anderson T . Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment. J Clin Pharmacol. 2018; 58(10):1314-1323. PMC: 6175428. DOI: 10.1002/jcph.1131. View

Tsai T, Lee C, Cheng C, Fang Y, Chung S, Chen S . Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice. Cells. 2019; 8(6). PMC: 6628350. DOI: 10.3390/cells8060589. View

Mosenzon O, Blicher T, Rosenlund S, Eriksson J, Heller S, Hels O . Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019; 7(7):515-527. DOI: 10.1016/S2213-8587(19)30192-5. View

Karsdal M, Henriksen K, Bay-Jensen A, Molloy B, Arnold M, John M . Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol. 2010; 51(4):460-71. DOI: 10.1177/0091270010372625. View

Knudsen L, Lau J . The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019; 10:155. PMC: 6474072. DOI: 10.3389/fendo.2019.00155. View

Breton-Romero R, Weisbrod R, Feng B, Holbrook M, Ko D, Stathos M . Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus. J Am Heart Assoc. 2018; 7(18):e009379. PMC: 6222937. DOI: 10.1161/JAHA.118.009379. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

10.

Husain M, Birkenfeld A, Donsmark M, Dungan K, Eliaschewitz F, Franco D . Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019; 381(9):841-851. DOI: 10.1056/NEJMoa1901118. View

11.

Larsen J, Hylleberg B, Ng K, Damsbo P . Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care. 2001; 24(8):1416-21. DOI: 10.2337/diacare.24.8.1416. View

12.

Knauf C, Cani P, Perrin C, Iglesias M, Maury J, Bernard E . Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest. 2005; 115(12):3554-63. PMC: 1297248. DOI: 10.1172/JCI25764. View

13.

Cristina Castelli M, Wong D, Friedman K, Riley M . Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. Clin Ther. 2011; 33(7):934-45. DOI: 10.1016/j.clinthera.2011.05.088. View

14.

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

15.

Hunt J, Smith J, Jiang C . Effect of meal volume and energy density on the gastric emptying of carbohydrates. Gastroenterology. 1985; 89(6):1326-30. DOI: 10.1016/0016-5085(85)90650-x. View

16.

Mentlein R . Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept. 1999; 85(1):9-24. DOI: 10.1016/s0167-0115(99)00089-0. View

17.

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

18.

Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I . Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther. 2009; 84(4):468-74. DOI: 10.1038/clpt.2008.35. View

19.

Jensen L, Helleberg H, Roffel A, Van Lier J, Bjornsdottir I, Pedersen P . Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017; 104:31-41. DOI: 10.1016/j.ejps.2017.03.020. View

20.

Htike Z, Zaccardi F, Papamargaritis D, Webb D, Khunti K, Davies M . Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2016; 19(4):524-536. DOI: 10.1111/dom.12849. View